I'm sure many on this board understand what I'm about to say but maybe there are some who have not experienced "stock option incentive plans". I was offered an executive position at a Fortune 50 company and as part of the compensation package a stock plan was included. Quarterly allocations were given at 20% less than the current price of the stock on the NYSE. You had 5 years to exercise the options so this became a real incentive to stay with the company and produce value so the company would continue to grow and the stock value would rise. IMO this is what the management team at Cytodyn is preparing for in the near term. I doubt they are requesting this increase to line their pockets but better prepare them to entice the best people to come to the company and help it grow.

I look at this request and the timing and it means to me that they are preparing now for the soon to be approved Leronlimab and rather than being behind the curve to manage growth, they are preparing for this when it occurs. I personally will be voting "For" this stock incentive plan.